The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

ShareA translational biomedical research hub in Nigeria, Helix Biogen Institute (HBI) has appointed Emmanuel Adediran as ...